Denovan‑Wright, Eileen - Dalhousie University

研究领域

Professor Denovan-Wright and her students are exploring the potential of cannabinoids for treatment of Huntington’s disease and other neurodegenerative disorders. Lately, the group has been very interested in unique pharmacology of the endocannabinoids and newly discovered allosteric modulators of cannabinoid receptors and the interplay between these compounds, intracellular signaling and gene expression.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM. J Biol Chem. 2014 Sep 5;289(36):24845-62. doi: 10.1074/jbc.M114.557025. Epub 2014 Jul 18. PMID: 25037227 The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients. Laprairie RB, Warford JR, Hutchings S, Robertson GS, Kelly ME, Denovan-Wright EM. J Neuroimmunol. 2014 Feb 15;267(1-2):61-72. doi: 10.1016/j.jneuroim.2013.12.008. Epub 2013 Dec 12. PMID:24360910 Co-expression of the human cannabinoid receptor coding region splice variants (hCB₁) affects the function of hCB₁ receptor complexes. Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. Eur J Pharmacol. 2013 Dec 5;721(1-3):341-54. doi: 10.1016/j.ejphar.2013.09.002. Epub 2013 Oct 1. PMID:24091169 Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease. Laprairie RB, Kelly ME, Denovan-Wright EM. Neuropharmacology. 2013 Sep;72:47-57. doi: 10.1016/j.neuropharm.2013.04.006. Epub 2013 Apr 16. PMID:23602984 The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription. Laprairie RB, Kelly ME, Denovan-Wright EM. Br J Pharmacol. 2012 Dec;167(8):1583-95. doi: 10.1111/j.1476-5381.2012.02175.x. Review. PMID:22924606